EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glucagon‐like peptide agonists: A prospective review

Zamara Mariam, Sarfaraz K Niazi iD

Endocrinology, Diabetes & Metabolism · 2024-01 · 7 (1)

DOI: 10.1002/edm2.462 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 14.12.2023. Verfasst von Zamara Mariam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Scientist, Inc., Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as promising therapeutic options for addressing Type‐2 diabetes, obesity, and related conditions. Among these, semaglutide, tirzepatide, liraglutide etc., all notable GLP‐1RA, have gained attention owing to their favourable pharmacological properties and clinical efficacy.

Aims

This comprehensive review aims to provide a detailed analysis of both the currently available GLP‐1RAs in the market and those undergoing clinical trials. The focus is on examining their mechanism of action, pharmacokinetics, efficacy in glycemic control and weight management, safety profile, and potential applications. Materials & Methods The review employs a systematic approach to gather information on GLP‐1RAs. Relevant literature from the currently literature and ongoing clinical trials is thoroughly examined. Detailed scrutiny is applied to understand the mechanism of action, pharmacokinetic properties, and clinical outcomes of these agents.

Results

The review presents a comprehensive overview of the GLP‐1RAs, highlighting their distinct mechanisms of action, pharmacokinetic profiles, and clinical effectiveness in glycemic control and weight management. Safety profiles are also discussed, providing a holistic understanding of these therapeutic agents.

Discussion

The findings are discussed in the context of advancements in the field of GLP‐1RAs. Potential applications beyond diabetes and obesity are explored, shedding light on the broader implications of these agents in managing related conditions.

Conclusion

In conclusion, this review underscores the significance of GLP‐1RAs, with a specific focus on semaglutide, in the management of type 2 diabetes, obesity, and beyond. By synthesizing information on their mechanisms, pharmacokinetics, efficacy, and safety, this review provides valuable insights into the potential benefits these agents offer, contributing to the ongoing discourse in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansHypoglycemic AgentsProspective StudiesGlucagon-Like PeptidesObesityGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1GLP-2cancerdiabetesglucagonhormonesneurological disorders

Substanzen

Hypoglycemic AgentsGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Pharmaceutical Scientist, Inc., Chicago, Illinois, USA.
  • College of Pharmacy, University of Illinois, Chicago, Illinois, USA.

ORCID-Profile: Sarfaraz K Niazi

Zitieren

APA

Mariam, Z., & Niazi, S. K. (2024). Glucagon‐like peptide agonists: A prospective review. Endocrinology, Diabetes & Metabolism, 7(1). https://doi.org/10.1002/edm2.462

Vancouver

Mariam Z, Niazi SK. Glucagon‐like peptide agonists: A prospective review. Endocrinology, Diabetes & Metabolism. 2024;7(1). doi:10.1002/edm2.462

BibTeX
@article{Mariam2024,
  author = {Mariam, Zamara and Niazi, Sarfaraz K},
  title = {Glucagon‐like peptide agonists: A prospective review},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2024},
  volume = {7},
  number = {1},
  doi = {10.1002/edm2.462}
}
Kostenlos starten →